2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
To evaluate the effect of parenteral supplementation of fishoil based emulsion (rich in omega-3 fatty acids) compared with a soy bean oil emulsion (rich in omega-6 fatty acids) on the leukocyte functions (amongst others production of TNF-α and other…